System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Richard A Kanaan is an expert in Psychiatry at Austin Health (Australia). As of October 2026, ScienceLeadR ranks Richard A Kanaan in the top 1% of experts worldwide for Conversion Disorder and Somatoform Disorders. Richard A Kanaan has authored 178 publications, the most recent in 2026, and is an investigator in 1 clinical trial, 1 of them ongoing. SLR score: 629 (community average: 125). How the SLR is computed.

LeadR Profile

Richard A Kanaan Austin Health Australia
629 ScienceLeadR Reputation 629

Unlock

Register Login
Network Map

Psychiatry

Subspecialties: Neurology - Psychology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2005 - 2026
Source: PubMed

King's College London

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 178

Citations

Citations: 5 438 1st author: 37 Last author: 62 Unique author: 14

Main journals

J Neurol Neurosurg Psychiatry 16
Epilepsy Behav 7
J Psychosom Res 7
Aust N Z J Psychiatry 6
Psychosomatics 6

Best Journals

Lancet Neurol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Empowering recovery: the role of self-management in motor-functional neurological disorder.
PMID 42898702 — self-management, conversion disorder, rehabilitation, recycling, self care, nervous system diseases		Front Neurol20260
After the Trip: A Qualitative Study of Healthy Individuals' Motor Experiences Following Different Doses of Psilocybin.
PMID 42886634 — safety, psilocybin, hallucinogens, research, therapeutics		Brain Behav20260
Effect of dispositional optimism and pessimism on the relationship between stressful life events and late-life depression.
PMID 42567210 — depression, pessimism, optimism		J Affect Disord20260
Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.
PMID 42566154 — physical therapists, safety, psilocybin, healthy volunteers, drug-related side effects and adverse reactions, hallucinogens, movement		CNS Drugs20260
(Es)ketamine in functional neurological disorder: a systematic review.
PMID 42548890 — conversion disorder, ketamine, signs and symptoms, therapeutics, nervous system diseases		Front Psychiatry20261

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 1

By status:

Recruiting 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 1
multicentric5to9 0
multicentricup10 0

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Silexan in the Treatment Of Posttraumatic Stress Disorder Trial
NCT06412757 — stress disorders, post-traumatic, pharmaceutical preparations, stress, physiological, psychotherapy, drug therapy, signs and symptoms, drug-related side effects and adverse reactions, capsules, stress disorders, traumatic, anxiety disorders, therapeutics, generalized anxiety disorder		Phase 3Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS